International Journal of Cardiology Cardiovascular Risk and Prevention · Oct 29, 2026
Personalizing postpartum cardiovascular prevention after preeclampsia: Is routine statin therapy justified in normotensive survivors? A critical narrative review
By Naja S
BACKGROUND: Preeclampsia is a pregnancy-related cardiovascular risk-enhancing factor associated with increased lifetime cardiovascular disease (CVD) risk. However, long-term cardiovascular risk varies according to postpartum blood pressure, metabolic health, and development of conventional cardiovascular risk factors. CURRENT CLINICAL RECOMMENDATIONS: Current guidelines recognize preeclampsia as a risk-enhancing factor to support cardiovascular risk assessment and shared decision-making regarding lipid-lowering therapy. However, preeclampsia alone is not an indication for routine statin therapy, and no postpartum low-density lipoprotein cholesterol (LDL-C) target is recommended solely on the basis of previous preeclampsia. EVIDENCE GAP: Existing evidence is derived mainly from observational studies involving heterogeneous populations. Few studies have evaluated women who remain normotensive with favorable metabolic profiles, and no completed randomized trial has demonstrated that postpartum statin therapy improves long-term cardiovascular outcomes. MAIN ARGUMENT: Lifelong cardiovascular surveillance is warranted after preeclampsia, but routine statin therapy for all survivors is not supported. Lipid-lowering therapy should be individualized according to overall cardiovascular risk. FUTURE DIRECTIONS: Future studies should identify high-risk phenotypes, validate postpartum risk prediction tools such as PREVENT, and determine whether selected women benefit from targeted statin therapy.
doi.org/10.1016/j.ijcrp.2026.200725Open accessPubMed 43036767Interventions